Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
‘First of its kind’ medication can significantly reduce heart attacks and strokes
A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...
Medpage Today on MSN18h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
News Medical on MSN13h
Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
The Lancet18h
Sodium–glucose co-transporter inhibitors—who would have guessed?
Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...
Medical News Today11h
Can drugs like Ozempic help with COPD?
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...